This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes

This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes

Sulphonylureas (SU) have received a terrible press in recent years. A series of publications over many years have told us that SUs increase the risk of adverse cardiovascular outcomes in diabetes patients (usually relative to metformin in observational studies),1 analyses from ACCORD and other mega...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Ryder, R, Holman, R, Gwilt, M
Fformat:	Conference item
Cyhoeddwyd:	Association of British Clinical Diabetologists 2016

Eitemau Tebyg

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
gan: Holman, R, et al.
Cyhoeddwyd: (1987)

Sulphonylureas in the management of type 2 diabetes: To be or not to be?
gan: André J. Scheen
Cyhoeddwyd: (2021-01-01)

Sulphonylurea therapy over six years does not delay progression to diabetes
gan: Herlihy, O, et al.
Cyhoeddwyd: (2000)

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
gan: Cull, C, et al.
Cyhoeddwyd: (2000)

Sulphonylureas and hypoglycaemia.
gan: Ferner, R, et al.
Cyhoeddwyd: (1988)

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
gan: Eeley, E, et al.
Cyhoeddwyd: (1996)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
gan: Matthews, DR, et al.
Cyhoeddwyd: (1998)

Factors influencing utilization of different types of sulphonylureas amongst type 2 diabetes patients
gan: Huri, H.Z., et al.
Cyhoeddwyd: (2010)

UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group.
gan: Eeley, E, et al.
Cyhoeddwyd: (1996)

Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment
gan: Misra, S, et al.
Cyhoeddwyd: (2018)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
gan: Turner, R, et al.
Cyhoeddwyd: (1998)

New uses for old drugs: neonatal diabetes and sulphonylureas.
gan: Ashcroft, F
Cyhoeddwyd: (2010)

Neonatal Diabetes Caused by Activating Mutations in the Sulphonylurea Receptor
gan: Peter Proks
Cyhoeddwyd: (2013-06-01)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
gan: Matthews, DR, et al.
Cyhoeddwyd: (1998)

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM
gan: Rachman, J, et al.
Cyhoeddwyd: (1996)

Extent of satisfaction with tablets and food-timing in sulphonylurea-treated diabetes.
gan: Woodcock, A, et al.
Cyhoeddwyd: (2007)

Should I believe all the truths?
gan: Greenberg, A
Cyhoeddwyd: (2018)

Pharmacogenetics in Type 2 diabetes: variation in TCF7L2 influences response to sulphonylureas
gan: Pearson, E, et al.
Cyhoeddwyd: (2007)

Stem cells in cancer : should we believe or not? /
gan: Grande, Enrique, et al.
Cyhoeddwyd: (2014)

Sulphonylureas and the rise and fall of beta-cell function
gan: Matthews, DR, et al.
Cyhoeddwyd: (2005)

Identification of First Case of Neonatal Diabetes in Singapore and Successful Conversion from Insulin to Sulphonylurea
gan: Rashida Vasanwala MD (Paeds), MRCPCH (UK), et al.
Cyhoeddwyd: (2010-06-01)

The clinical aspects ot the sulphonylurea compounds from the position of the cardioprotective approach at patient with type 2 diabetes, using glucocardiomonitoring
gan: N. A. Chernikova, et al.
Cyhoeddwyd: (2022-10-01)

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
gan: Degli Esposti L, et al.
Cyhoeddwyd: (2014-10-01)

Interactions between nicorandil and sulphonylureas: a structural basis.
gan: Reimann, F, et al.
Cyhoeddwyd: (2001)

Should metformin remain the first-line therapy for treatment of type 2 diabetes?
gan: Chelsea Baker, et al.
Cyhoeddwyd: (2021-01-01)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
gan: Fournier, Marie, et al.
Cyhoeddwyd: (2014-10-01)

Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels.
gan: Ammälä, C, et al.
Cyhoeddwyd: (1996)

Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?
gan: Geoffrey Hackett
Cyhoeddwyd: (2020-07-01)

Homozygous hypomorphic HNF1A alleles are a novel cause of young-onset diabetes and result in sulphonylurea sensitive diabetes
gan: Misra, S, et al.
Cyhoeddwyd: (2020)

Effects of protein phosphorylation on the sulphonylurea receptor of the pancreatic beta-cell.
gan: Niki, I, et al.
Cyhoeddwyd: (1997)

Binding of sulphonylureas to plasma proteins – a KATP channel perspective
gan: Proks, P, et al.
Cyhoeddwyd: (2018)

Alternative MDR splicing is required for direct potentiation of exocytosis by sulphonylureas
gan: Wendt, A, et al.
Cyhoeddwyd: (2001)

Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
gan: Peter Proks, et al.
Cyhoeddwyd: (2018-01-01)

Should an echocardiographic scan be done routinely for infants of diabetic mothers?
gan: M Vural, et al.
Cyhoeddwyd: (1995-10-01)

A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.
gan: Proks, P, et al.
Cyhoeddwyd: (2006)

Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.
gan: Hansen, A, et al.
Cyhoeddwyd: (2002)

To believe or not to believe
gan: Chistine Kuruç
Cyhoeddwyd: (1989-12-01)

Continued Dispensing: what medications do patients believe should be available?
gan: Salem Hasn Abukres, et al.
Cyhoeddwyd: (2015-05-01)

Lack of association between KCNJ11 (rs5219) and ABCC8 (rs757110) polymorphisms and sulphonylurea treatment response in type 2 diabetes patients in Novosibirsk region
gan: Irina Arkad'evna Bondar, et al.
Cyhoeddwyd: (2015-03-01)

Involvement of the n-terminus of Kir6.2 in coupling to the sulphonylurea receptor.
gan: Reimann, F, et al.
Cyhoeddwyd: (1999)